Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...

Start the day smarter. Get all the news you need in your inbox each morning. From wireless wearables and ...